What Is/Juvenile Diabetes/Chesapeake/Make A Donation
JDRF prioritizes its funding for type 1 diabetes research in four interrelated therapeutic areas: autoimmune therapies, β-cell therapies, prevention of complications, and glucose control. Each therapeutic area encompasses a diverse portfolio of research programs that span from exploratory to preclinical proof-of-principle and on to clinical proof-of-concept research. The organization’s overarching strategy focuses on addressing critical gaps and challenges, catalyzing innovative and transformational research, advancing and translating research, creating collaborations, and accelerating time lines at all stages of research development. To facilitate downstream partnering and follow-on funding, JDRF increasingly supports product development by “de-risking” projects, thereby decreasing the barriers of entry for future funders. The Health Care and Social Assistance industry includes establishments and services such as:
hospitals, nursing and residential care facilities and out-patient care centres; offices of health practitioners (i.e. dentists, doctors, optometrists and chiropractors); medical and diagnostic laboratories; home health care services; ambulance services; social assistance services (i.e. for children, youth, the elderly, families); community food, housing, emergency and relief services; vocational rehabilitation services; and daycare services See full list of Media Credits http://broadcaster.beazil.net/public/credits/youtube/videos/42006 Founded by parents determined to find a cure for their children with T1D, JDRF expanded through grassroots fundraising and advocacy efforts to become a powerhouse in the scientific community with more than 100 U.S. locations and six international affiliates. We’ve funded nearly $2 billion in research to date and made significant progress in understanding and fighting the disease. We must keep up the pace of funding so progress doesn’t slow or stop entirely. You’re the reason for our success. Every dollar we put toward research comes from donations. So when you support JDRF with your time, talent, voice and, yes, your money, you enable us to advance even more research. There are many ways to join the JDRF family, but for 45 years there has been only one reason—because we are the organization that will turn Type One into Type None. Chesapeake is an independent city located in the U.S. commonwealth of Virginia. As of the 2010 census, the population was 222,209, in 2013, the population was estimated to be 232,977, making it the third-most populous city in Virginia.
Chesapeake is included in the Virginia Beach–Norfolk–Newport News, VA–NC MSA. One of the cities in the South Hampton Roads, Chesapeake was organized in 1963 by voter referendums approving the political consolidation of the city of South Norfolk with the remnants of the former Norfolk County, which dated to 1691. (Much of the territory of the county had been annexed by other cities.) Chesapeake is the second-largest city by land area in the Commonwealth of Virginia.
In 2011, Chesapeake was named the 21st best city in America by Bloomberg Businessweek. JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF has led the search for a cure for T1D since our founding in 1970. In those days, people commonly called the disease “juvenile diabetes” because it was frequently diagnosed in, and strongly associated with, young children. Our organization began as the Juvenile Diabetes Foundation. Later, to emphasize exactly how we planned to end the disease, we added a word and became the Juvenile Diabetes Research Foundation.Today, we know an equal number of children and adults are diagnosed every day—approximately 110 people per day.
It makes sense to mention the main issues –
Recipe Swap,Bolus Basel,JDRFCC,Pre- Diabetes,Glipizide,JDRF,Insulin Pump,UKPDS Study,Virginia,Diabetes Care,sugar diabetes,research,Levemir,negative diabetes associated autoantibodies,The Walk to Cure Diabetes,Translating Research Into Action for Diabetes Study,bariatric surgery,Insulin,diabetes diagnosis,worldwide effort,70/30 insulin,T1D Triggers,insulin pump therapy,juvenile diabetes,OGTT,Novolin N,elevated insulin levels,patient-driven care,glycemic targets,plasma glucose criteria,tolazamide,insulin therapy,low-density lipoprotein cholesterol,T1D management,Bolus insulin,Bag of Hope,Clinical Trial,life-changing breakthroughs,CONCEPTT,charity,Research,Ketoacidosis,DKA,very-low-density lipoprotein cholesterol,funding,Kussmaul breathing,JDRF One Walk,Juvenile Diabetes Foundation,save a life,get support,Diabetic Ketoacidosis,impaired glucose tolerance,insulin dependent,Chapter Volunteer Outreach Chairs,IGT,donate,Juvenile diabetes foundation,2-h PG value,Derek Rapp,insulin deficiency,Blood Glucose Meters,JDRF Mentor Program,Juvenile Diabetes Research.